Prime Medicine Prices $125 Million Offering At $3.50 To Fund Liver-Disease Research
The new shares account for about 17% of the stated post-offering total, with initial liver-disease trial data expected in 2027.
Prime Medicine, which develops genetic medicines that rewrite DNA, priced a $125 million offering Tuesday at $3.50 a share—about 19% below Monday's $4.30 close. The 35,714,286 new shares account for about 17% of the prospectus supplement's stated 216,451,834 shares after the offering, excluding the underwriters' option; the supplement was filed Thursday.
$117.1 Million After Offering Costs
Prime expects net proceeds of approximately $117.1 million after commissions and estimated expenses. That would rise to approximately $134.7 million if the underwriters use their option in full.
Jefferies, TD Cowen, Goldman Sachs, Oppenheimer and LifeSci Capital have 30 days to buy up to 5,357,142 additional shares. Full exercise would bring the prospectus's stated post-offering share count to 221,808,976.
Prime estimated its September 30 cash and short-term investments at $61.2 million, excluding $13.7 million of restricted cash. Those figures are preliminary and unaudited, and remain subject to its financial closing process.
The Money Targets Liver Programs
Prime intends to use the proceeds alongside its existing cash and investments to "primarily support the advancement of our Wilson disease and AATD programs and other research and development activities," according to the prospectus supplement. AATD refers to alpha-1 antitrypsin deficiency. The company assigns the remainder to "working capital, capital expenditures and other general corporate purposes."
The company reported dosing the first patient in its Wilson disease trial in October. Its candidate, PM577a, received U.S. FDA clearance to begin testing in July, following clearance in New Zealand in June.
The FDA cleared PM647, its alpha-1 antitrypsin deficiency candidate, for clinical testing in September. That allows an early-to-mid-stage global study beginning in the United States. Prime expects initial clinical data from both liver-disease trials in 2027.
Research Beyond The Liver
Prime's business combines its own treatment candidates with research and licensing partnerships. Its Prime Editing technology aims to correct DNA changes that cause disease.
The Cystic Fibrosis Foundation funds its cystic fibrosis research through grants. Prime also works with Bristol-Myers Squibb on treatments using immune cells edited outside the body; the September 2024 collaboration brought a $55 million upfront payment.
Prime continues FDA discussions about an approval application for PM359, its chronic granulomatous disease treatment, planned for the first half of 2027.
Prime launched the offering Tuesday. PRME shares closed Wednesday at $4.30, above the $3.50 offering price.
The underwriters expect to deliver the shares on or about Thursday; the offering remains priced, with delivery pending.
Sources
- Form 424B5 — Prime Medicine, Inc. (PRME) — SEC EDGAR
- Prime Medicine Announces Pricing of Public Offering of Common Stock | Morningstar — morningstar.com
- Prime Medicine Announces Pricing of Public Offering of — globenewswire.com
- Prime Medicine Announces Proposed $125.0 Million Public — globenewswire.com